Well… company is basically worthless.
gone from having phase 2 trials running to 2 very early pre-clinical assets.
assume Mautner will resign and have to take responsibility for the failed strategy. I hope GK will find a buyer for his shares at whatever price these fall to and also sell out so the company can clean slate.
I plan to just hold and check in few years from now.
Ann: Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs, page-2
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
